Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPPER study: dapagliflozin effect on albuminuria in heart failure with type 2 diabetes mellitus
jRCTs051180135Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of dapagliflozin in type 2 diabetes mellitus (T2DM), chronic heart failure (CHF) and diabetic glomerulosclerosis (2 arms), sponsored by AstraZeneca. Started May 2017; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic heart failure (CHF)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCTs051180135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180135.